List of Progenics Pharmaceuticals patents

Patents where

Current Assignee

Name

Progenics Pharmaceuticals

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 11544407 Systems and methods for secure cloud-based medical image upload and processing	Patent 11544407 was granted and assigned to Progenics Pharmaceuticals on January, 2023 by the United States Patent and Trademark Office.	Progenics Pharmaceuticals	Progenics Pharmaceuticals	United States Patent and Trademark Office	11544407	January 3, 2023
‌ US Patent 7446177 Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection	Patent 7446177 was granted and assigned to Progenics Pharmaceuticals on November, 2008 by the United States Patent and Trademark Office.		Progenics Pharmaceuticals	United States Patent and Trademark Office	7446177	November 4, 2008
‌ US Patent 7736649 Methods of inhibiting human immunodeficiency virus infection through the administration of synergistic combinations of anti-CCR5 monoclonal antibodies, fusion inhibitors, and CD4-GP120 binding inhibitors	Patent 7736649 was granted and assigned to Progenics Pharmaceuticals on June, 2010 by the United States Patent and Trademark Office.		Progenics Pharmaceuticals	United States Patent and Trademark Office	7736649	June 15, 2010
‌ US Patent 7138119 Compositions and methods for inhibition of HIV-1 infection	Patent 7138119 was granted and assigned to Progenics Pharmaceuticals on November, 2006 by the United States Patent and Trademark Office.		Progenics Pharmaceuticals	United States Patent and Trademark Office	7138119	November 21, 2006
‌ US Patent 8986697 Antibodies for the treatment of	Patent 8986697 was granted and assigned to Progenics Pharmaceuticals on March, 2015 by the United States Patent and Trademark Office.		Progenics Pharmaceuticals	United States Patent and Trademark Office	8986697	March 24, 2015
‌ US Patent 11424035 Network for medical image analysis, decision support system, and related graphical user interface (GUI) applications	Patent 11424035 was granted and assigned to Progenics Pharmaceuticals on August, 2022 by the United States Patent and Trademark Office.	Progenics Pharmaceuticals	Progenics Pharmaceuticals	United States Patent and Trademark Office	11424035	August 23, 2022
‌ US Patent 7345153 Compounds capable of inhibiting HIV-1 infection	Patent 7345153 was granted and assigned to Progenics Pharmaceuticals on March, 2008 by the United States Patent and Trademark Office.		Progenics Pharmaceuticals	United States Patent and Trademark Office	7345153	March 18, 2008
‌ US Patent 9597327 Synthesis of (R)-N-methylnaltrexone	Patent 9597327 was granted and assigned to Progenics Pharmaceuticals on March, 2017 by the United States Patent and Trademark Office.	Progenics Pharmaceuticals	Progenics Pharmaceuticals	United States Patent and Trademark Office	9597327	March 21, 2017
‌ US Patent 8343992 Synthesis of	Patent 8343992 was granted and assigned to Progenics Pharmaceuticals on January, 2013 by the United States Patent and Trademark Office.		Progenics Pharmaceuticals	United States Patent and Trademark Office	8343992	January 1, 2013
‌ US Patent 7674904 Synthesis of R-N-methylnaltrexone	Patent 7674904 was granted and assigned to Progenics Pharmaceuticals on March, 2010 by the United States Patent and Trademark Office.		Progenics Pharmaceuticals	United States Patent and Trademark Office	7674904	March 9, 2010
‌ US Patent 7563899 (S)-	Patent 7563899 was granted and assigned to Progenics Pharmaceuticals on July, 2009 by the United States Patent and Trademark Office.		Progenics Pharmaceuticals	United States Patent and Trademark Office	7563899	July 21, 2009
‌ US Patent 7939083 Soluble, stabilized, proteolytically cleaved, trimeric HIV-1 gp140 proteins comprising modifications in the N-terminus of the gp41 ectodomain	Patent 7939083 was granted and assigned to Progenics Pharmaceuticals on May, 2011 by the United States Patent and Trademark Office.		Progenics Pharmaceuticals	United States Patent and Trademark Office	7939083	May 10, 2011
‌ US Patent 7935797 CCR5 chemokine receptor-specific monoclonal antibodies capable of inhibiting HIV-1 cell fusion	Patent 7935797 was granted and assigned to Progenics Pharmaceuticals on May, 2011 by the United States Patent and Trademark Office.		Progenics Pharmaceuticals	United States Patent and Trademark Office	7935797	May 3, 2011
‌ US Patent 7858298 Methods of inhibiting human immunodeficiency virus type 1 (HIV-1) infection through the administration of CCR5 chemokine receptor antagonists	Patent 7858298 was granted and assigned to Progenics Pharmaceuticals on December, 2010 by the United States Patent and Trademark Office.		Progenics Pharmaceuticals	United States Patent and Trademark Office	7858298	December 28, 2010
‌ US Patent 8003794 (	Patent 8003794 was granted and assigned to Progenics Pharmaceuticals on August, 2011 by the United States Patent and Trademark Office.		Progenics Pharmaceuticals	United States Patent and Trademark Office	8003794	August 23, 2011
‌ US Patent 9669096 Stable pharmaceutical formulations of methylnaltrexone	Patent 9669096 was granted and assigned to Progenics Pharmaceuticals on June, 2017 by the United States Patent and Trademark Office.	Progenics Pharmaceuticals	Progenics Pharmaceuticals	United States Patent and Trademark Office	9669096	June 6, 2017
‌ US Patent 7901685 Methods for assaying inhibition of HIV-1 envelope glycoprotein-mediated membrane fusion	Patent 7901685 was granted and assigned to Progenics Pharmaceuticals on March, 2011 by the United States Patent and Trademark Office.		Progenics Pharmaceuticals	United States Patent and Trademark Office	7901685	March 8, 2011
‌ US Patent 7862994 Methods for inhibiting HIV-1 envelope glycoprotein-medicated membrane fusion	Patent 7862994 was granted and assigned to Progenics Pharmaceuticals on January, 2011 by the United States Patent and Trademark Office.		Progenics Pharmaceuticals	United States Patent and Trademark Office	7862994	January 4, 2011
‌ US Patent 10376584 Stable pharmaceutical formulations of methylnaltrexone	Patent 10376584 was granted and assigned to Progenics Pharmaceuticals on August, 2019 by the United States Patent and Trademark Office.	Progenics Pharmaceuticals	Progenics Pharmaceuticals	United States Patent and Trademark Office	10376584	August 13, 2019
‌ US Patent 8471022 Preparation and use of (R),(R)-2,2′-bis-methylnaltrexone	Patent 8471022 was granted and assigned to Progenics Pharmaceuticals on June, 2013 by the United States Patent and Trademark Office.		Progenics Pharmaceuticals	United States Patent and Trademark Office	8471022	June 25, 2013
‌ US Patent 8916706 Preparation and use of (R),(R)-2,2′-bis-methylnaltrexone	Patent 8916706 was granted and assigned to Progenics Pharmaceuticals on December, 2014 by the United States Patent and Trademark Office.	Progenics Pharmaceuticals	Progenics Pharmaceuticals	United States Patent and Trademark Office	8916706	December 23, 2014
‌ US Patent 7118859 Methods for inhibiting HIV-1 infection	Patent 7118859 was granted and assigned to Progenics Pharmaceuticals on October, 2006 by the United States Patent and Trademark Office.		Progenics Pharmaceuticals	United States Patent and Trademark Office	7118859	October 10, 2006
‌ US Patent 8916581 (S)-			Progenics Pharmaceuticals	United States Patent and Trademark Office	8916581	December 23, 2014
‌ US Patent 8552025 Stable methylnaltrexone preparation			Progenics Pharmaceuticals	United States Patent and Trademark Office	8552025	October 8, 2013
‌ US Patent 7022323 Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection	Patent 7022323 was granted and assigned to Progenics Pharmaceuticals on April, 2006 by the United States Patent and Trademark Office.		Progenics Pharmaceuticals	United States Patent and Trademark Office	7022323	April 4, 2006

Results per page:

31 results

0 selected

31 results

0 selected